AEGiS-CATIE: DMP 266 -- new drug looks good

DMP 266 -- new drug looks good

TreatmentUpdate78 - Vol. 7, No. 8; June 1997
Sean Hosein

The new anti-HIV drug DMP 266, which is related to nevirapine and delavirdine, is being studied in combination with other drugs at several hospitals in the US. We now report results from the first 10 months of one of those studies.

Study details

Doctors recruited 30 volunteers (4 female, 26 male) who had never used protease inhibitors or drugs related to DMP 266. At the start of the study, the average CD4+ count was 270 cells and the amount of HIV in the blood was 87,000 copies. All subjects received 2.4 g/day of indinavir alone for 2 weeks, after which the dose was increased to 3 g/day for 21 subjects who in addition received 200 mg/day of DMP 266. The remaining 9 subjects continued to receive indinavir alone. By the 6th month of the study, these 9 subjects were also given d4T and DMP 266 and their dose of indinavir was raised to 3 g/day.

Results

Combination therapy resulted in a dramatic decrease in the amount of HIV in the blood, with 80% of subjects showing less than 400 copies/ml. An average increase of about 140 CD4+ cells was also observed. These benefits were maintained through the 10th month of the study. Four people receiving both DMP 266 and indinavir reported rashes.

Other studies underway include combinations of DMP 266 (at higher doses) with nelfinavir or ritonavir. Clinical trials with this new drug are supposed to take place later this year in Canada.

REFERENCES:

1. Wagner K, Kahn J, Mayers D et al.Long term activity and tolerability of DMP 266 in combination with indinavir. Eighth European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, 27 May 1997, poster 3043.

970601
CATE7802

ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users l This article first appeard in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1997 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca

Disclaimer: The editors have taken all such care as they consider reasonable in preparing this database, but they cannot be held responsible for any inaccuracies or mis-statements of fact contained herein. Inclusion in this database of any information on any treatment, therapy, or clinical trial in no way represents an endorsement of that treatment, therapy, or trial by ÆGiS or any of its sponsors. This data should always be used in conjunction with professional medical advice.
©1997. ÆGiS.